Rituximab as the first-line treatment in newly diagnosed systemic lupus erythematosus
ObjectivesRituximab (RTX) has been commonly used for the treatment of patients with severe or refractory systemic lupus erythematosus (SLE), yet real-world data concerning RTX as the first-line treatment in newly diagnosed moderate-to-severe SLE patien…